Home
|
Site Map
|
Contact Us
Our Company
Our Presentations
Where You Can Meet Us
Our Clients
Contact Us
Company Principals
Science and Policy Advisors
Team Directors
Pharmaceutical Risk Management
Over-The-Counter Strategic Services
Strategic Communications
Issues Management
Marketing Strategy
Clinical Pharmacology
Clinical and Behavioral Research
Data Management and Statistical Analysis
Risk Management Program for a New Formulation
Abuse Liability Assessment and Risk Assessment for a New Formulation of a Stimulant Pharmaceutical
Risk Management for a Marketed Schedule II Product
Issues Management and Strategic Publications for an OTC Switch
Clinical and Behavioral Research
Marketing & Communications
Pharmacology
Scientific & Public Policy
Methodology, Data Management & Analysis
Pharmaceutical Risk Management
Clinical and Behavioral Research
Marketing & Communications
Pharmacology
Scientific & Public Policy
Methodology, Data Management & Analysis
Pharmaceutical Risk Management
Where You Can Meet Us
You can meet
Pinney
Associates at scientific meetings throughout the year.
-
view schedule
Recent Publication
Ferguson SG, Shiffman S, Gitchell JG, Sembower MA, West R.
-
Unplanned quit attempts--results from a U.S. sample of smokers and ex-smokers. Nicotine Tob Res. 2009 Jul;11(7):827-32.
-
view abstract
Call Us
Bethesda, MD 301-718-8440
Pittsburgh, PA 412-687-5677
-
more contact options
Pharmaceutical Risk Management
-
email to a friend
Peer-Reviewed Publications on Pharmaceutical Risk Management Authored by
Pinney
Associates Staff and Scientific Consultants.
1
2
3
next page >
McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, Wissel J, Waxman D, Carter LP, Seeger V, Johnson RE.
Case histories in pharmaceutical risk management. Drug Alcohol Depend. 2009 Sep 18. [Epub ahead of print]
Henningfield JE, Schuster CR.
Risk management and post-marketing surveillance of CNS drugs. Drug Alcohol Depend. 2009 Sep 18. [Epub ahead of print]
Dasgupta N, Schnoll SH.
Signal detection in post-marketing surveillance for controlled substances. Drug Alcohol Depend. 2009 Jul 17. [Epub ahead of print]
Wright C 4th, Schnoll S, Bernstein D.
Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective. Ann N Y Acad Sci. 2008 Oct;1141:284-303. Review.
Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, Grudzinskas C, Jasinski D, Lande SD, Passik SD, Schnoll SH, Sellers E, Travers D, Weiss R.
Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007 Oct;23(8):648-60.
1
2
3
next page >
Site Map
|
About Us
|
Our Experts
|
Practice Areas
|
Case Studies
|
Publications
|
Privacy Policy
Copyright © 2005 PinneyAssociates
Powered by
Janmedia Interactive, Inc.
